Publikationen von Alex Sigal

Sigal, A.: Milder disease with Omicron: is it the virus or the pre-existing immunity? Nature Reviews Immunology (2022)

Rodel, H. E.; Ferreira, I. A. T. M.; Ziegler, C. G. K.; Ganga, Y.; Bernstein, M.; Hwa, S.-H.; Nargan, K.; Lustig, G.; Kaplan, G.; Noursadeghi, M. et al.; Shalek, A. K.; Steyn, A. J. C.; Sigal, A.: Aggregated Mycobacterium tuberculosis Enhances the Inflammatory Response. Frontiers in Microbiology 12, 757134 (2021)

Kolloli, A.; Kumar, R.; Singh, P.; Narang, A.; Kaplan, G.; Sigal, A.; Subbian, S.: Aggregation state of Mycobacterium tuberculosis impacts host immunity and augments pulmonary disease pathology. Commun Biol. 4 (1) (2021)

Karim, F.; Gazy, I.; Cele, S.; Zungu, Y.; Krause, R.; Bernstein, M.; Khan, K.; Ganga, Y.; Rodel, H.; Mthabela, N. et al.; Mazibuko, M.; Muema, D.; Ramjit, D.; Ndung'u, T.; Hanekom, W.; Gosnell, B.; COMMIT-KZN Team; Lessells, R. J.; Wong, E. B.; de Oliveira, T.; Moosa, M.-Y. S.; Lustig, G.; Leslie, A.; Kløverpris, H.; Sigal, A.: HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. eLife 10, e67397 (2021)

Lustig, G.; Cele, S.; Karim, F.; Derache, A.; Ngoepe, A.; Khan, K.; Gosnell, B. I.; Moosa, M.-Y. S.; Ntshuba, N.; Marais, S. et al.; Jeena, P. M.; Govender, K.; Adamson, J.; Kløverpris, H.; Gupta, R. K.; Harrichandparsad, R.; Patel, V. B.; Sigal, A.: T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. PLoS Pathogens 9, e1009871 (2021)

Snyman, J.; Hwa, S.-H.; Krause, R.; Muema, D.; Reddy, T.; Ganga, Y.; Karim, F.; Leslie, A.; Sigal, A.; Ndung'u, T. et al.; Team, C.-K.: Similar antibody responses against SARS-CoV-2 in HIV uninfected and infected individuals on antiretroviral therapy during the first South African infection wave. Clinical Infectious Diseases, ciab758 (2021)

Skelly, D. T.; Harding, A. C.; Gilbert-Jaramillo, J.; Knight, M. L.; Longet, S.; Brown, A.; Adele, S.; Adland, E.; Brown, H.; Team, M. L. et al.; Tipton, T.; Stafford, L.; Mentzer, A. J.; Johnson, S. A.; Amini, A.; Tan, T. K.; Schimanski, L.; Huang, K.-Y. A.; Rijal, P.; Frater, J.; Goulder, P.; Conlon, C. P.; Jeffery, K.; Dold, C.; Pollard, A. J.; Sigal, A.; de Oliveira, T.; Townsend, A. R.; Klenerman, P.; Dunachie, S. J.; Barnes, E.; Carroll, M. W.; James, W. S.: Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications 12 (1) (2021)

Faulkner, N.; Ng, K. W.; Wu, M. Y.; Harvey, R.; Margaritis, M.; Paraskevopoulou, S.; Houlihan, C.; Hussain, S.; Greco, M.; Bolland, W. et al.; Warchal, S.; Heaney, J.; Rickman, H.; Spyer, M.; Frampton, D.; Byott, M.; de Oliveira, T.; Sigal, A.; Kjaer, S.; Swanton, C.; Gandhi, S.; Beale, R.; Gamblin, S. J.; McCauley, J. W.; Daniels, R. S.; Howell, M.; Bauer, D.; Nastouli, E.; Kassiotis, G.: Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife, e69317 (2021)

Madhi, S. A.; Baillie, V.; Cutland, C. L.; Voysey, M.; Koen, A. L.; Fairlie, L.; Padayachee, S. D.; Dheda, K.; Barnabas, S. L.; Bhorat, Q. E. et al.; Briner, C.; Kwatra, G.; Ahmed, K.; Aley, P.; Bhikha, S.; Bhiman, J. N.; Bhorat, A. E.; du Plessis, J.; Esmail, A.; Groenewald, M.; Horne, E.; Hwa, S.-H.; Jose, A.; Lambe, T.; Laubscher, M.; Malahleha, M.; Masenya, M.; Masilela, M.; McKenzie, S.; Molapo, K.; Moultrie, A.; Oelofse, S.; Patel, F.; Pillay, S.; Rhead, S.; Rodel, H.; Rossouw, L.; Taoushanis, C.; Tegally, H.; Thombrayil, A.; van Eck, S.; Wibmer, C. K.; Durham, N. M.; Kelly, E. J.; Villafana, T. L.; Gilbert, S.; Pollard, A. J.; de Oliveira, T.; Moore, P. L.; Sigal, A.; Izu, A.; NGS-SA Group, . t. W.-V. C. G.: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. The New England Journal of Medicine: NEJM / Publ. by the Massachusetts Medical Society 384 (20), S. 1885 - 1898 (2021)

Cele, S.; Gazy, I.; Jackson, L.; Hwa, S.-H.; Tegally, H.; Lustig, G.; Giandhari, J.; Pillay, S.; Wilkinson, E.; Naidoo, Y. et al.; Karim, F.; Ganga, Y.; Khan, K.; Bernstein, M.; Balazs, A. B.; Gosnell, B. I.; Hanekom, W.; Moosa, M.-Y. S.; Africa, N. f. G. S. i. S.; Team, C.-K.; Lessells, R. J.; de Oliveira, T.; Sigal, A.: Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593 (7857), S. 142 - 146 (2021)

Garcia-Beltran, W. F.; Lam, E. C.; Denis, K. S.; Nitido, A. D.; Garcia, Z. H.; Hauser, B. M.; Feldman, J.; Pavlovic, M. N.; Gregory, D. J.; Poznansky, M. C. et al.; Sigal, A.; Schmidt, A. G.; Iafrate, A. J.; Naranbhai, V.; Balazs, A. B.: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184 (9), S. 2372 - 2383 (2021)

Tegally, H.; Wilkinson, E.; Giovanetti, M.; Iranzadeh, A.; Fonseca, V.; Giandhari, J.; Doolabh, D.; Pillay, S.; San, E. J.; Msomi, N. et al.; Mlisana, K.; von Gottberg, A.; Walaza, S.; Allam, M.; Ismail, A.; Mohale, T.; Glass, A. J.; Engelbrecht, S.; Zyl, G. V.; Preiser, W.; Petruccione, F.; Sigal, A.; Hardie, D.; Marais, G.; Hsiao, N.-Y.; Korsman, S.; Davies, M.-A.; Tyers, L.; Mudau, I.; York, D.; Maslo, C.; Goedhals, D.; Abrahams, S.; Laguda-Akingba, O.; Alisoltani-Dehkordi, A.; Godzik, A.; Wibmer, C. K.; Sewell, B. T.; Lourenço, J.; Alcantara, L. C. J.; Pond, S. L. K.; Weaver, S.; Martin, D.; Lessells, R. J.; Bhiman, J. N.; Williamson, C.; de Oliveira, T.: Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592 (7854), S. 438 - 443 (2021)

Tegally, H.; Wilkinson, E.; Lessells, R. J.; Giandhari, J.; Pillay, S.; Msomi, N.; Mlisana, K.; Bhiman, J. N.; von Gottberg, A.; Walaza, S. et al.; Fonseca, V.; Allam, M.; Ismail, A.; Glass, A.; Engelbrecht, S.; Zyl, G. V.; Preiser, W.; Williamson, C.; Petruccione, F.; Sigal, A.; Gazy, I.; Hardie, D.; Hsiao, N.-y.; Martin, D.; York, D.; Goedhals, D.; San, E. J.; Giovanetti, M.; Lourenço, J.; Alcantara, L. C. J.; de Oliveira, T.: Sixteen novel lineages of SARS-CoV-2 in South Africa. Nature Medicine (2021)

Cromarty, R.; Sigal, A.; Liebenberg, L. J.; Mckinnon, L. R.; Karim, S. S. A.; Passmore, J.-A. S.; Archary, D.: Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. Journal of Investigative Medicine 2020, 001424 (2020)

Naicker, N.; Sigal, A.; Naidoo, K.: Metformin as Host-Directed Therapy for TB Treatment: Scoping Review. Frontiers in Microbiology 11, 435 (2020)

Moyano, A.; Lustig, G.; Rodel, H. E.; Antal, T.; Sigal, A.: Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. PLoS Computational Biology 16 (2), e1007482 (2020)

Cromarty, R.; Sigal, A.; Liebenberg, L. J. P.; McKinnon, L. R.; Karim, S. S. A.; Passmore, J.-A. S.; Archary, D.: Diminished HIV Infection of Target CD4+ T Cells in a Toll-Like Receptor 4 Stimulated in vitro Model. Frontiers in immunology 10, 1705 (2019)

Barichievy, S.; Naidoo, J.; Boullé, M.; Scholefield, J.; Parihar, S. P.; Coussens, A. K.; Brombacher, F.; Sigal, A.; Mhlanga, M. M.: Viral Apoptosis Evasion via the MAPK Pathway by Use of a Host Long Noncoding RNA. Frontiers in Cellular and Infection Microbiology 8, 263 (2018)

Jackson, L.; Hunter, J.; Cele, S.; Ferreira, I. M.; Young, A. C.; Karim, F.; Madansein, R.; Dullabh, K. J.; Chen, C.-Y.; Buckels, N. J. et al.; Ganga, Y.; Khan, K.; Boulle, M.; Lustig, G.; Neher, R. A.; Sigal, A.: Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death. eLife 7, e30134 (2018)

Kim, J. T.; Chang, E.; Sigal, A.; Baltimore, D.: Dendritic cells efficiently transmit HIV to T Cells in a tenofovir and raltegravir insensitive manner. PLoS One 13 (1), e0189945 (2018)